Callan Family Office LLC Purchases 2,149 Shares of HCA Healthcare, Inc. $HCA

Key Points

• Callan Family Office LLC has increased its stake in HCA Healthcare, Inc. by 101.9% during the second quarter, now owning a total of 4,258 shares valued at approximately $1.63 million.
• Recent analysis has been positive for HCA Healthcare, with several firms upgrading their ratings, including Wall Street Zen raising it from "hold" to "buy" and a consensus target price of $422.31.
• The company reported earnings of $6.84 EPS for the last quarter, exceeding analysts' expectations, while also declaring a quarterly dividend of $0.72 per share.

Callan Family Office LLC increased its position in HCA Healthcare, Inc. (NYSE:HCA - Free Report) by 101.9% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 4,258 shares of the company's stock after purchasing an additional 2,149 shares during the quarter. Callan Family Office LLC's holdings in HCA Healthcare were worth $1,631,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of the stock. Blair William & Co. IL raised its holdings in HCA Healthcare by 5.0% in the 2nd quarter. Blair William & Co. IL now owns 9,000 shares of the company's stock valued at $3,448,000 after acquiring an additional 425 shares during the period. US Bancorp DE raised its holdings in HCA Healthcare by 0.8% in the 2nd quarter. US Bancorp DE now owns 18,864 shares of the company's stock valued at $7,227,000 after acquiring an additional 155 shares during the period. Fulton Breakefield Broenniman LLC bought a new position in HCA Healthcare in the 2nd quarter valued at about $201,000. Optas LLC raised its holdings in HCA Healthcare by 13.2% in the 2nd quarter. Optas LLC now owns 727 shares of the company's stock valued at $279,000 after acquiring an additional 85 shares during the period. Finally, First Merchants Corp bought a new position in shares of HCA Healthcare during the second quarter worth approximately $201,000. 62.73% of the stock is owned by institutional investors.

Insiders Place Their Bets

In related news, EVP Michael S. Cuffe sold 3,836 shares of HCA Healthcare stock in a transaction on Monday, September 8th. The shares were sold at an average price of $418.84, for a total transaction of $1,606,670.24. Following the completion of the transaction, the executive vice president owned 31,503 shares of the company's stock, valued at $13,194,716.52. This trade represents a 10.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 1.30% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on the stock. Wall Street Zen raised shares of HCA Healthcare from a "hold" rating to a "buy" rating in a report on Saturday, July 5th. Weiss Ratings reaffirmed a "buy (b-)" rating on shares of HCA Healthcare in a report on Wednesday. Cantor Fitzgerald reiterated an "overweight" rating and set a $444.00 price target on shares of HCA Healthcare in a research report on Tuesday, October 7th. Bank of America increased their price target on shares of HCA Healthcare from $375.00 to $410.00 and gave the stock a "neutral" rating in a research report on Wednesday, September 10th. Finally, Truist Financial increased their price target on shares of HCA Healthcare from $390.00 to $415.00 and gave the stock a "buy" rating in a research report on Wednesday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $422.31.

HCA Healthcare Price Performance

Shares of HCA Healthcare stock opened at $414.73 on Friday. HCA Healthcare, Inc. has a fifty-two week low of $289.98 and a fifty-two week high of $439.01. The firm has a market capitalization of $97.04 billion, a P/E ratio of 17.43, a P/E/G ratio of 1.31 and a beta of 1.40. The company's 50 day moving average price is $405.12 and its two-hundred day moving average price is $375.85.

HCA Healthcare (NYSE:HCA - Get Free Report) last issued its quarterly earnings results on Friday, July 25th. The company reported $6.84 EPS for the quarter, topping analysts' consensus estimates of $6.20 by $0.64. The company had revenue of $18.61 billion for the quarter, compared to analyst estimates of $18.49 billion. HCA Healthcare had a net margin of 8.21% and a negative return on equity of 7,363.11%. HCA Healthcare's revenue was up 6.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $5.50 earnings per share. HCA Healthcare has set its FY 2025 guidance at 25.500-27.000 EPS. On average, analysts expect that HCA Healthcare, Inc. will post 24.98 earnings per share for the current year.

HCA Healthcare Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 30th. Stockholders of record on Tuesday, September 16th were issued a dividend of $0.72 per share. This represents a $2.88 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Tuesday, September 16th. HCA Healthcare's payout ratio is 12.11%.

HCA Healthcare Company Profile

HCA Healthcare, Inc, through its subsidiaries, owns and operates hospitals and related healthcare entities in the United States. It operates general and acute care hospitals that offers medical and surgical services, including inpatient care, intensive care, cardiac care, diagnostic, and emergency services; and outpatient services, such as outpatient surgery, laboratory, radiology, respiratory therapy, cardiology, and physical therapy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.